Drug Type Single-domain antibody, Therapeutic radiopharmaceuticals |
Synonyms 177Lu BOT1712, Lutetium-177-BOT1712 |
Target |
Mechanism PDGFRβ modulators(Platelet-derived growth factor receptor beta modulators), Ionising radiation emitters |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colonic Cancer | Preclinical | NL | 31 Jul 2023 |